Newly recognized cutaneous drug eruptions.
Many new drugs are entering the marketplace and although some cutaneous reactions might be noted in the preclinical evaluation, some of the reactions, particularly those that are rare, will not be noted until the drugs enter widespread use. In addition, distinctive reactions may occur, as is the case with epidermal growth factor-receptor inhibitors. Careful observation and evaluation might result in a better understanding of "naturally" occurring skin disease.
Callen
Jeffrey P
JP
Division of Dermatology, University of Louisville School of Medicine, Louisville, KY 40292, USA. jefca@aol.com
D000970:Antineoplastic Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000175:diagnosis*; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D008178:Lupus Erythematosus, Cutaneous / Q000139:chemically induced* / Q000175:diagnosis; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects
D000970:Antineoplastic Agents; D007155:Immunologic Factors; D010726:Phosphodiesterase Inhibitors